Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
Tilray Brands Inc. (TLRY) maintains a dynamic presence in global cannabis markets through its medical research initiatives and consumer product innovations. This resource provides investors and industry observers with centralized access to verified corporate announcements, regulatory developments, and market analysis.
Users will find updates spanning earnings reports, international expansion efforts, and product portfolio enhancements, including developments in cannabis-infused wellness solutions. The curated selection enables stakeholders to track operational milestones across Tilray's pharmaceutical-grade production facilities and lifestyle brand divisions.
All content undergoes strict verification to ensure alignment with financial disclosure standards and industry regulations. Regular updates reflect Tilray's position as a GMP-certified producer serving medical markets in 20+ countries while expanding recreational offerings in emerging markets.
Bookmark this page for streamlined monitoring of Tilray's strategic initiatives, quality control advancements, and responses to evolving cannabis legislation worldwide.
Breckenridge Brewery, a renowned Colorado craft brewer, is opening a new location in Fort Collins in early August 2024. The 10,000-square-foot facility will feature a full-service restaurant and brewery, employing 40 staff members including head brewer Ryan Joy. To celebrate, Breckenridge is hosting a First Pour Party on August 17th, 2024, featuring live music, local vendors, and raffles. The event will showcase a commemorative beer and crowler, with proceeds benefiting Project C.U.R.E. The new location aims to blend Breckenridge's legacy with innovative brewing and community collaboration, offering an elevated dining experience alongside their craft beers.
Tilray Brands reported strong financial results for fiscal 2024, with a 26% increase in net revenue to $789 million. Key highlights include:
- Cannabis net revenue grew 24% to $273 million
- Beverage-alcohol net revenue surged 113% to $202 million
- Reduced net convertible debt by ~$300 million
- Achieved positive adjusted free cash flow of $6.6 million
- Completed strategic acquisitions of eight craft beer brands, HEXO Corp, and Truss Beverage Co
The company's diversification strategy has positioned it as a leader in cannabis, beverages, and wellness across multiple regions. Tilray is now the 5th largest craft brewer in the U.S. and holds the #1 recreational cannabis market share in Canada.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) announced that its subsidiary Aphria RX GmbH has received a trading license in Germany. This license allows Aphria RX to sell and distribute a wide range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany. The development significantly expands Tilray's commercial growth opportunities in the German market.
With both cannabis cultivation and trade licenses, Tilray is now well-positioned to capitalize on the growing market opportunity in Germany. This further strengthens Tilray's position as a global leader in cannabis research, cultivation, production, and distribution. The company remains committed to advocating for responsible cannabis regulations, education, research, and accessibility to high-quality medical cannabis.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has achieved another milestone in European medical cannabis. The company received approval for its second medical cannabis extract in Portugal, Tilray Oral Solution THC10:CBD10. This follows the earlier approvals of Tilray Medical whole flower THC 18 and the first cannabis extract in Portugal.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, emphasized the significance of this approval in expanding medical cannabis offerings for Portuguese patients. The company views this as a important step in meeting patient care needs and providing high-quality cannabis products for specific medical conditions.
Tilray Medical operates in over 20 countries, offering a diverse portfolio of EU-GMP certified medicinal cannabis products. The company remains committed to supporting global medical cannabis patient care through quality products accessible via healthcare practitioners.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has announced that its German subsidiary, Aphria RX GmbH, has received the first new cannabis cultivation license under Germany's new Cannabis Act (MedCanG). This license allows Aphria RX to increase production by approximately 5 times and introduce new strains, enhancing patient access across Germany.
Key points:
- Aphria RX can now cultivate and manufacture a broader range of medical cannabis
- The facility can expand from 3 to 31 approved strains
- Aphria RX was designed with guidance from Kevin Anderson of Broken Coast Cannabis
- The new license positions Tilray to capitalize on Germany's growing medical cannabis market
This development is expected to significantly improve access to high-quality, German-produced medical cannabis for patients nationwide.
SweetWater Brewing Company, a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), has launched Rowdy Peach IPA in collaboration with Atlanta United FC. This new brew, with 6.8% ABV, celebrates the team's passionate fans and soccer culture. The IPA features juicy peach aromas and comes in red and black cans, inspired by the team's colors and supporter chant.
Rowdy Peach IPA is available at Atlanta United home matches, SweetWater's taproom, in six-packs, and on draft. As the team's official craft beer partner, SweetWater is enhancing the gameday experience with tailgate activations and watch parties. The partnership aims to deepen connections with the Atlanta community and soccer fans nationwide.
Manitoba Harvest, a subsidiary of Tilray Brands (NASDAQ: TLRY; TSX: TLRY), has introduced new Coffee and Chocolate flavors to its Organic Bioactive Fiber supplement line, developed in partnership with Brightseed®. These products aim to enhance gut wellness and healthy digestion, offering 7g of fiber per serving for the Chocolate flavor and 6g of fiber with 60mg of caffeine for the Coffee variant.
The supplements utilize upcycled hemp hulls containing unique bioactives to support gut health. New research published in the Journal of Dietary Supplements highlights the potential of hemp hulls and Bio Gut Fiber to enhance gut health, including support for healthy gut barrier function and metabolic wellbeing. A pre-clinical study also confirmed the prebiotic activity of Brightseed® Bio Gut Fiber.
The new products are available for $19.99 on manitobaharvest.com and select US retailers, with Amazon availability coming soon.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company, has announced the release date for its fourth quarter and full fiscal year 2024 financial results. The results will be disclosed on July 29, 2024, after market close.
Following the release, Tilray will host a live audio webcast at 4:30 pm Eastern Time to discuss the results. Investors can access the webcast through the Investors section of Tilray's website. Additionally, stockholders can submit and upvote questions via the Say Technologies platform until July 26, 2024, for the upcoming Q&A session.
Tilray Brands (Nasdaq: TLRY; TSX: TLRY) has announced the launch of its new Good Supply vape lineup, featuring a variety of 1G 510 vapes with distinctive flavors. The flavors include Banana Kush, Blue Dream, Blue Raspberry, Cherry Loops, Frozen Watermelon, Gooey Gold, Mango Passionfruit, Mountain Mist, Orange Swirl, Pineapple Express, Purple Monkey, Rocket Bomb, and Tropical Chewy Bear.
In addition to flavorful offerings, Good Supply emphasizes sustainability with biodegradable vape mouthpieces and hemp tube containers. These products can be composted in organic processing or landfill facilities, aligning with Good Supply's eco-friendly initiatives.
The new vape products are available at select retailers across Canada, just in time for the 710 celebrations.
Tilray Medical, a division of Tilray Brands (Nasdaq: TLRY; TSX: TLRY), announced a new scientific study titled 'Medical Cannabis for Patients Over Age 50.' The study, conducted across multiple sites, involved 299 participants with an average age of 66.7 years, 62.2% of whom were female. Approximately 90% of the participants used medical cannabis to treat pain-related conditions such as chronic pain and arthritis.
The study found significant improvements in pain scores, sleep, and quality of life among the participants. Additionally, there was a notable reduction in the use of other medications, suggesting that medical cannabis could be a cost-effective treatment option. This study emphasizes the growing importance of medical cannabis for older adults and reinforces Tilray's commitment to advancing medical research and providing quality medical cannabis products.
FAQ
What is the current stock price of TILRAY BRANDS (TLRY)?
What is the market cap of TILRAY BRANDS (TLRY)?
